Navigation Links
Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data
Date:6/11/2009

Boston Biotech Firm Reports First Rise in 76 Years of Replikin Count* of H1N1 Lethality Gene

Boston (PRWeb) June 11, 2009-- As the World Health Organization raised its pandemic alert to phase 6, the top of its six-point scale, a new analysis released yesterday (June 10) of the latest peptide genomic data for the H1N1 influenza virus shows that the current global outbreak of H1N1 is increasing in its capacity for lethality. The new sequence data on PubMed of the past two weeks through June 10, 2009 showed an increase in the Replikin Count* of the Replikin Lethality Gene in the pB1 genomic area from a mean of 2 in 2008 to a mean of 3.2 in 2009 (p<0.001). The Replikin Count of the Lethality Gene in 836 previous H1N1 influenza virus isolates has remained essentially unchanged (at 2) since 1933.

These analyses were conducted by the Boston-based biotech firm Replikins, Ltd. (www.replikins.com) using its FluForecast® software. A year ago (4/7/08), using the same software, the firm predicted the current H1N1 virus outbreak, and last month (5/23/09) an increase in the Replikin Count of the Replikin Infectivity Gene in the hemagglutinin area indicated a marked increase in infectivity of the evolving H1N1 virus.
   
"Last month the H1N1 genomic data indicated some bad and some good news. While it indicated an increase in the infectivity of the H1N1 virus, its lethality appeared to remain relatively low," noted Sam Bogoch MD PhD, chairman of Replikins Ltd. "However, the FluForecast® analysis of new data of the past few weeks , through June 10th, on 144 new specimens published on PubMed, indicate an increase in the current H1N1 outbreak's capacity for lethality. Since the software also permitted the automated analysis of all sequence data available on PubMed for all previous years, it was noted that this is the first such significant increase in the Replikin Count of the H1N1 Lethality Gene in 76 years. This is cause for concern and an accelerated vaccine effort."
   
For both the Infectivity Gene and the Lethality Gene, a significant increase in Replikin Count has invariably been followed by an increase in infectivity or lethality in influenza. Both the Replikin Infectivity Gene and the Replikin Lethality Gene have been found to act independently in all common influenza strains in human, swine, and bird hosts.
   
The company recently announced that it has made available for testing against H1N1 a Two-Punch™ PanFlu™ vaccine. The same vaccine system has been successfully tested against H5N1 in chickens.

About Replikins Ltd.
Replikins, LLC. (www.replikins.com), a Boston-based biotech company, and Replikins,Ltd., develop and market novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV. The company's predictive products and vaccines in development are based upon the company's discovery of Replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique products to predict the emergence of virulent strains of particular diseases(FluForecast™) and is designing synthetic vaccines specifically tailored to combat a given strain and against shared properties of several strains (Syntope™ vaccines). The company is partnering with governments and the private sector in providing predictive tools and vaccines in furtherance of the public health initiative to prevent and combat epidemics.

*The company's vaccines and predictive tools are based on the company's discovery of a new group of peptides related to rapid replication called Replikins, whose increase in concentration in virus or other organism proteins (Replikin Count™ = number of replikins per 100 amino acids) is associated with rapid replication.

Contact: John McKenney
jmckenney(at)replikins(dot)com
617-536-0220

###

Read the full story at http://www.prweb.com/releases/Replikins/H1N1/prweb2526654.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
3. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
4. NIH scientists describe ways to better assess benefits of influenza vaccine in the elderly
5. Launch of New Educational Campaign, Spread the Word - NOT the Flu!, Aims to Highlight Importance of Influenza Vaccination
6. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
7. Influenza: Insights into cell specificity of human vs. avian viruses
8. Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates
9. Health Department Reports States First Lab-Confirmed Influenza Case of the Season
10. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
11. Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: